SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Sick Visit — John Henry Holliday
| Patient | John Henry Holliday |
|---|
| Date of birth | 2004-08-14 |
|---|
| Identifiers | MRN HR-NI007-SYN; SSN (made up) 000-07-8153 |
|---|
| Document date | 2026-05-19 |
|---|
| Author | Martin Beaumont, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Chief Complaint
Nausea, vomiting, and loose stools for two days during tuberculosis treatment. [S]
History of Present Illness
Mr. Holliday is a 21-year-old dentist with drug-susceptible cavitary pulmonary tuberculosis in the sixth week of the continuation phase of isoniazid and rifampin, given by video-observed therapy, and with a mild alcohol use disorder. Two days ago he developed nausea and loose stools, and he vomited twice yesterday; two coworkers at the dental office had a stomach illness last week. When he reported the nausea on his video call this morning, the health department nurse told him to hold today's doses, as his treatment plan instructs, and to be seen today with liver tests. He has no yellowing of the eyes or skin, no dark urine or pale stools, no pain under the right ribs, and no itching or rash. His cough has gone and he has had no fevers or night sweats. He has not missed any other dose. He told us that nine days ago, at a friend's birthday party, he drank about six whiskeys over an evening, the first time he has drunk heavily since starting treatment; he has not drunk since. He feels he let himself down but has no thoughts of suicide. [S]
| Element | Detail |
|---|
| Onset | Two days ago |
| Location | Upper abdomen and bowel |
| Duration | Two days |
| Character | Nausea, two vomits, and loose stools |
| Severity | Mild to moderate; drinking fluids |
| Timing | Sixth week of the continuation phase |
| Context | Coworkers with a stomach illness; one evening of heavy drinking nine days ago |
| Modifying factors | Today's doses held on the nurse's advice |
| Associated signs and symptoms | No jaundice, dark urine, right upper abdominal pain, rash, or fever |
Review of Systems
| System | Result | Finding |
|---|
| Constitutional | Positive | Tired with the illness; no fever or night sweats |
| Eyes | Negative | No yellowing of the eyes; vision normal |
| Respiratory | Negative | No cough, sputum, or breathlessness |
| Gastrointestinal | Positive | Nausea, two vomits yesterday, and loose stools; no right upper abdominal pain, blood, or pale stools |
| Genitourinary | Negative | Urine orange from rifampin as expected, not dark brown |
| Integumentary | Negative | No jaundice, rash, or itching |
| Neurological | Negative | No numbness or tingling of the hands or feet |
| Psychiatric | Negative | Disappointed about the party; no thoughts of suicide or self-harm |
8 systems reviewed. [S]
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Rifampin 300 mg capsules, two capsules (600 mg) daily | 600 mg once daily on an empty stomach by video-observed therapy with the health department, seven days a week, for six months | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
| Pyrazinamide 500 mg tablets, three tablets (1500 mg) daily | 1500 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase | Oral route | 2026-02-12 to 2026-04-08 | completed | S |
| Ethambutol 400 mg tablets, three tablets (1200 mg) daily | 1200 mg once daily by video-observed therapy with the health department, seven days a week, until susceptibility results return | Oral route | 2026-02-12 to 2026-03-10 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-02-12 to 2026-08-13 | completed | S |
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 2026-05-19 | Body height | 178 | cm | S |
| 2026-05-19 | Body weight | 61.8 | kg | S |
| 2026-05-19 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 2026-05-19 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-05-19 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-05-19 | Heart rate | 98 | /min | S |
| 2026-05-19 | Respiratory rate | 16 | /min | S |
| 2026-05-19 | Body temperature | 37.4 | Cel | S |
| 2026-05-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-05-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 64 | U/L | 7-56 U/L | High | S |
| 2026-05-19 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 58 | U/L | 10-40 U/L | High | S |
| 2026-05-19 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-19 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 98 | U/L | 40-129 U/L | Normal | S |
| 2026-05-19 | Total score [AUDIT-C] | 4 | {score} | | | S |
Physical Exam
Vital signs recorded on 2026-05-19; see the Vital Signs section. [S]
| System | Finding |
|---|
| General | Tired but well-appearing; weight 61.8 kg, down 0.7 kg from the last visit |
| Eyes | No scleral icterus |
| Mouth | Mucous membranes slightly dry |
| Respiratory | Clear; a few fine crackles at the right apex that clear with coughing |
| Abdomen | Soft, mildly tender around the umbilicus; liver not enlarged or tender; no guarding |
| Skin | No jaundice or rash |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Pulmonary tuberculosis, right upper lobe cavitary, sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed |
A15.0 | S — Synthetic modern coding of his documented pulmonary tuberculosis at the time of diagnosis; the bacteriology is synthetic. |
| Alcohol use disorder, mild, with binge drinking | active | confirmed |
F10.10 | S — Synthetic modern coding anchored to the documented heavy drinking; the severity and the criteria met are synthetic. |
| Acute viral gastroenteritis during tuberculosis treatment, with a mild aminotransferase rise below the threshold for drug-induced liver injury; resolved | resolved | confirmed |
A08.4 | S — Synthetic intercurrent illness chosen to teach the assessment of nausea on isoniazid and rifampin; it does not echo a documented illness. |
Assessment and Plan
- Acute viral gastroenteritis (A08.4). A short illness shared with coworkers, with loose stools, no fever, and a benign abdomen. ALT 64 and AST 58 U/L are only just above normal, with normal bilirubin 0.9 and alkaline phosphatase 98. Drug-induced liver injury is defined as ALT at least three times the upper limit with symptoms, or five times without; ALT here is about 1.1 times the upper limit, so this is not drug-induced liver injury. The small rise fits the recent heavy drinking and the viral illness. [S]
- Oral fluids and a bland diet; no antiemetic needed now.
- Hand washing; stay off work until two days after the symptoms stop.
- Pulmonary tuberculosis, continuation phase (A15.0). Clinically well on treatment, with no cough or fever. One day's doses held today. [S]
- Resume isoniazid and rifampin tomorrow under video-observed therapy once he can keep food down; the missed dose is added at the end, so the last dose moves one day later.
- Repeat liver tests in two weeks.
- Stop the doses and call the same day for yellow eyes or skin, dark urine, right upper abdominal pain, or vomiting that returns.
- Alcohol use disorder, mild, with one lapse (F10.10). One evening of heavy drinking after more than two months with little or none. AUDIT-C 4. A lapse he has reported openly. Safety reviewed: no thoughts of suicide; the 988 Suicide & Crisis Lifeline is in his phone. [S]
- Brief counseling today about the extra liver risk from alcohol on isoniazid; he recommits to no alcohol until treatment ends.
- Plan for parties: arrive with a non-alcoholic drink and leave early, and tell one friend his goal.
- Next session with his substance-use counselor this week.
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea (2017)
Follow-up: Health department nurse to confirm the restart on tomorrow's video call. Liver tests in two weeks. End-of-treatment visit in the summer. Next scheduled visit 2026-08-18: end-of-treatment review after six months. [S]